Figure 2.

The Kaplan–Meier estimates of cancer-specific survival (CSS) according to the clinical T stage (A), lymph node status (B), and tumor size stratified by a cutoff of 30 mm (C). The 2-year CSS rates were 94.2% and 54.0% for clinical ≤T2 and ≥T3 stages, respectively (p < 0.001; Figure 2A); 86.0% and 57.2% for patients with or without lymph node involvement, respectively (p = 0.009; Figure 1B); and 96.0% and 65.9% for tumor size of <30 mm and ≥30 mm, respectively (p < 0.001; Figure 1C).